Michael Odell
Papers
4
Total Citations
641
H-Index
4
About
Dr. Michael Odell is a leading clinician-researcher in head and neck surgical oncology, with a primary focus on oropharyngeal squamous cell carcinoma (OPSCC) and the comparative effectiveness of treatment modalities. His most defining contribution is his leadership of the landmark ORATOR clinical trial program. The phase 2 ORATOR trial, published in 2019 and cited over 458 times, was the first randomized study to directly compare primary radiotherapy (RT) against transoral robotic surgery (TORS) with neck dissection for early-stage OPSCC. This work provided critical, high-level evidence on swallowing outcomes and survival between these two curative-intent approaches, directly informing clinical decision-making for patients and surgeons worldwide. Dr. Odell subsequently reported the final five-year outcomes of the ORATOR trial in 2024, solidifying the long-term comparative data. Beyond his trial work, he has been instrumental in developing and establishing TORS programs within the Canadian healthcare system, authoring foundational papers on the unique barriers and implementation strategies for this technology in Canada. With a cumulative citation count exceeding 640 for his ORATOR-related work alone, Dr. Odell’s research has profoundly shaped the modern management of HPV-related oropharyngeal cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4Development of a transoral robotic surgery program in Canada5 citations · 2013